{"brief_title": "Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy", "brief_summary": "Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD chemotherapy.", "condition": ["Hodgkin Disease"], "intervention_type": ["Drug", "Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Filgrastim SD/01", "Adriamycin", "Bleomycin", "Vinblastine", "DTIC"], "arm_group_label": ["Filgrastim + ABVD Chemotherapy", "Filgrastim + ABVD Chemotherapy", "Filgrastim + ABVD Chemotherapy", "Filgrastim + ABVD Chemotherapy", "Filgrastim + ABVD Chemotherapy"], "other_name": ["G-CSF", "Neupogen", "Doxorubicin Hydrochloride", "Adriamycin PFS", "Adriamycin RDF", "Bleomycin sulfate", "Blenoxane", "BLM", "Velban", "DTIC-Dome", "Dacarbazine"], "criteria": "INCLUSION: - Previously untreated Hodgkin's disease patients who are scheduled to receive standard ABVD chemo. - Histologically proven diagnosis of Hodgkin's disease of any type. - Bidimensionally measurable disease. - Signed informed consent. - Age >/= 16 yrs. - Adequate bone marrow reserve (ANC>1000/uL, Platelet >100,000/uL. - LVEF>/=50% by MUGA scan or echocardiogram. - Serum creatinine <2mg/dL; serum bilirubin<2mg/dL. EXCLUSION: - HIV positive. - Pregnant women and those of child bearing age who are not using adequate contraception. - Prior chemotherapy. - Severe pulmonary disease including COPD and asthma. - History of prior sensitivity to E.coli derived products.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "granulocyte colony-stimulating factor", "mesh_term": ["Hodgkin Disease", "Doxorubicin", "Liposomal doxorubicin", "Bleomycin", "Vinblastine", "Dacarbazine", "Lenograstim"], "id": "NCT00038558"}